Overview
Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries
Status:
Completed
Completed
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of PfizerTreatments:
Everolimus
Sirolimus
Criteria
Inclusion Criteria:- Transplantation patients treated with sirolimus (Rapamune).
Exclusion Criteria:
- Patients must be able to give informed consent.